Alexion Pharmaceutical Inc. buy melinda
Start price
15.09.17
/
50%
€132.65
Target price
26.12.17
€175.89
Performance (%)
-18.99%
End price
26.12.17
€107.46
Summary
This prediction ended on 26.12.17 with a price of €107.46. The price of Alexion Pharmaceutical Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -18.99%. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Alexion Pharmaceutical Inc. | - | - | - | - |
iShares Core DAX® | 1.804% | -0.748% | 13.168% | 16.408% |
iShares Nasdaq 100 | -0.182% | -3.412% | 39.976% | 43.502% |
iShares Nikkei 225® | 0.413% | -7.381% | 18.776% | 2.874% |
iShares S&P 500 | 0.664% | -1.941% | 28.141% | 42.155% |
According to melinda what are the pros and cons of Alexion Pharmaceutical Inc. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Alexion Pharmaceutical Inc. diskutieren
Pharma SecteurProduits
Alexion fügt Paul A. Friedman, MD in den Vorstand
- Der ehemalige Präsident und CEO von Incyte bringt umfangreiche Erfahrung in F & E und Biotechnologie -
(Vom Mitglied beendet)
Stopped prediction by melinda for Alexion Pharmaceutical Inc.
Alexion Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€70.50
12.03.20
12.03.20
€145.00
04.11.21
04.11.21
119.55%
05.11.21
05.11.21
Could be worthwhile Investment >10% per year
Alexion Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€125.50
29.09.18
29.09.18
€130.79
12.03.20
12.03.20
-43.83%
12.03.20
12.03.20
Could be worthwhile Investment >10% per year
Alexion Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€112.84
09.03.18
09.03.18
€153.34
10.09.18
10.09.18
-6.26%
10.09.18
10.09.18
Could be worthwhile Investment >10% per year